Clinical Trials Logo

Lymphoma, Non-Hodgkin clinical trials

View clinical trials related to Lymphoma, Non-Hodgkin.

Filter by:

NCT ID: NCT00067002 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Randomized Double Cord Blood Transplant Study

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if combining cord blood units to make the cells "take" faster in recipients will help to improve the results of cord blood transplants.

NCT ID: NCT00066092 Completed - Lymphoma Clinical Trials

Pegfilgrastim PBPC Mobilization Study

Start date: April 2003
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize stem cells for autologous transplantation in patients with Hodgkin's or non-Hodgkin's lymphoma.

NCT ID: NCT00064246 Completed - Clinical trials for Recurrent Adult Diffuse Large Cell Lymphoma

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Start date: July 2003
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I/II trial to study the effectiveness of combining yttrium Y 90 ibritumomab tiuxetan with rituximab in treating patients who have localized or recurrent lymphoproliferative disorder after an organ transplant. Monoclonal antibodies such as yttrium Y 90 ibritumomab tiuxetan and rituximab can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells

NCT ID: NCT00064116 Completed - Lymphoma Clinical Trials

Combination Chemotherapy With or Without Rituximab in Non-Hodgkin's Lymphoma

IDEC-C2B8
Start date: May 8, 2001
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without rituximab in treating patients with non-Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is studying four different combination chemotherapy regimens and rituximab to see how well they work compared to four different combination chemotherapy regimens alone in treating patients with non-Hodgkin's lymphoma.

NCT ID: NCT00062894 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

Start date: April 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the blood pharmacokinetics in patients with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's lymphoma who have received a dosimetric dose of fission-derived iodine I 131 tositumomab.

NCT ID: NCT00062296 Completed - Lymphoma Clinical Trials

Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Start date: March 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy such as epirubicin use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining epirubicin with rituximab may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining epirubicin with rituximab in treating patients who have relapsed or refractory B-cell non-Hodgkin's lymphoma or chronic lymphocytic leukemia.

NCT ID: NCT00062114 Completed - Lymphoma Clinical Trials

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Start date: April 2004
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies such as yttrium Y 90 ibritumomab tiuxetan and rituximab can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well giving yttrium Y 90 ibritumomab tiuxetan together with rituximab works in treating patients with progressive non-Hodgkin's lymphoma.

NCT ID: NCT00061672 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to assess the safety and effectiveness of ABT-510 in subjects with refractory lymphoma.

NCT ID: NCT00061425 Completed - Clinical trials for Non-Hodgkin's Lymphoma

Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgG

Start date: August 2000
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this trial is to determine the safety of a 90Y-radiolabeled, humanized (CDR-grafted) form of the LL2 monoclonal antibody in patients with Non-Hodgkin's lymphoma (NHL) at different dose levels.

NCT ID: NCT00060684 Completed - Clinical trials for Lymphoma, Small Lymphocytic

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

Start date: December 2001
Phase: Phase 1
Study type: Interventional

The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.